Edgewise Therapeutics Files 8‑K/A Updating Financial Exhibits for Transaction

What Happened
Edgewise Therapeutics, Inc. (EWTX) filed a Current Report on Form 8‑K/A on July 16, 2026, to provide financial statements and exhibits under Item 9.01(b). The amendment supplements an earlier 8‑K (the "Initial Report") and explicitly states that it should be read in conjunction with that Initial Report for a more complete description of the referenced transaction.

Key Details

• Filing: Form 8‑K/A filed July 16, 2026 (Accession No. 0001104659-26-084088).
• Item reported: 9.01(b) — financial statements and exhibits were provided or updated.
• The amendment refers readers to the Initial Report for a full description of the Transaction; the 8‑K/A itself focuses on supplemental financial/exhibit materials.
• No other Form 8‑K items (e.g., earnings, executive changes, mergers beyond the referenced Transaction) were reported in this amendment.

Why It Matters
This filing supplies the supporting financial statements and exhibits related to a previously disclosed transaction, improving transparency for investors who want the underlying documentation. Retail investors should review both this 8‑K/A and the Initial Report to understand the transaction’s terms and any potential financial effects disclosed in the supplemental materials.